Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114028 | 0.81 | ALOX15 (0.57) | ALOX15ALDH1A1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL6106298 | 0.77 | MAPK1 (0.40) | ALDH1A1LMNASRCMAPK1CASP1 | |
| SCHEMBL3557023 | 0.76 | MAPT (0.46) | ALOX15ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3557021 | 0.76 | MAPT (0.46) | ALOX15ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2281613 | 0.75 | MAPK1 (0.33) | ALOX15ALDH1A1LMNANPSR1SRC | |
| SCHEMBL1447305 | 0.72 | HTT (0.38) | ALDH1A1LMNAMAPK1CASP1CASP7 | |
| SCHEMBL1448326 | 0.71 | PIK3CD (0.33) | MAPK1CASP1CASP7 | |
| SCHEMBL1447750 | 0.71 | KMT2A (0.33) | ALDH1A1NPSR1MAPK1CASP1CASP7 | |
| SCHEMBL8654020 | 0.70 | ALOX15 (0.57) | ALOX15ALDH1A1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL1447738 | 0.70 | PDE1C (0.39) | ALDH1A1NPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | ALOX15 876/4885ALDH1A1 320/4885LMNA 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.